Business
ABL Diagnostics Proposes a Significant Increase in Its Dividend for FY2025
WOIPPY, France, May 18, 2026--Regulatory News: ABL Diagnostics (Euronext Paris – FR001400AHX6), a company specialized in molecular diagnostics for infectious diseases, announces that its Board of Directors, at its meeting held on April 30, 2026, has decided to propose to the Combined General Meeting to be held on June 30, 2026 the distribution of a dividend of €0.11 per share for the financial year ended December 31, 2025.
About this update from Abl Diagnostics Sa
[{"type":"text","content":"Proposed dividend of €0.11 per share, up +120%, reflecting the Company’s improved financial performance and solid financial position","length":132,"tagName":"p","attribs":{}},{"type":"text","content":"WOIPPY, France, May 18, 2026--(BUSINESS WIRE)--Regulatory News:","length":63,"tagName":"p"},{"type":"text","content":"ABL Diagnostics (Euronext Paris – FR001400AHX6), a company specialized in molecular diagnostics for infectious diseases, announces that its Board of Directors, at its meeting held on April 30, 2026, has decided to propose to the Combined General Meeting to be held on June 30, 2026 the distribution of a dividend of €0.11 per share for the financial year ended December 31, 2025.","length":379,"tagName":"p"},{"type":"text","content":"This proposal, which remains subject to shareholders’ approval, is in line with the Company’s dividend policy, following the first dividend paid in respect of FY2024 in the amount of €0.05 per share. It reflects ABL Diagnostics’ intention to establish a sustainable shareholder return, consistent with its development and financial position.","length":341,"tagName":"p"},{"type":"text","content":"The proposed dividend amounts to approximately €1.77 million in aggregate and would, if approved, be detached on July 3, 2026, with payment scheduled for July 7, 2026, entirely in cash.","length":185,"tagName":"p"},{"type":"text","content":"This proposal comes in a context of significant improvement in the Company’s financial performance for FY2025. ABL Diagnostics reported revenue of €6.95 million, representing an increase of over 30% compared to the previous year, as well as net profit close to €1.0 million, reflecting strong growth. This performance was accompanied by a significant improvement in operating profitability and strengthened cash generation, allowing for a marked reduction in net debt.","length":468,"tagName":"p"},{"type":"text","content":"In this context, the proposed dividend distribution reflects ABL Diagnostics’ ability to combine business growth, improved profitability and financial discipline. It also illustrates a balanced approach between funding the investments required to support the Company’s development and sharing value creation with its shareholders.","length":330,"tagName":"p"},{"type":"text","content":"ABL Diagnostics continues to implement its strategy focused on expan...